Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Metagenomi (MGX) EBITDA (2023 - 2025)

Metagenomi (MGX) has disclosed EBITDA for 3 consecutive years, with -$22.6 million as the latest value for Q4 2025.

  • On a quarterly basis, EBITDA rose 6.94% to -$22.6 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$88.3 million, a 14.32% decrease, with the full-year FY2025 number at -$88.3 million, down 14.32% from a year prior.
  • EBITDA was -$22.6 million for Q4 2025 at Metagenomi, down from -$20.4 million in the prior quarter.
  • In the past five years, EBITDA ranged from a high of -$10.7 million in Q2 2024 to a low of -$25.3 million in Q1 2024.
  • A 3-year average of -$19.5 million and a median of -$20.0 million in 2023 define the central range for EBITDA.
  • Peak YoY movement for EBITDA: grew 18.64% in 2024, then crashed 87.93% in 2025.
  • Metagenomi's EBITDA stood at -$19.0 million in 2023, then decreased by 27.83% to -$24.3 million in 2024, then rose by 6.94% to -$22.6 million in 2025.
  • Per Business Quant, the three most recent readings for MGX's EBITDA are -$22.6 million (Q4 2025), -$20.4 million (Q3 2025), and -$20.2 million (Q2 2025).